SOPHiA DDM for Hereditary Cancers Solution enables Krsnaa to provide high-quality NGS tests that help to evaluate for hereditary cancers
SOPHiA GENETICS, a cloud-native software company in the healthcare space and a leader in data-driven medicine, announced that Krsnaa Diagnostics, is live on SOPHiA DDM technology. Krsnaa Diagnostics is using the SOPHiA DDM for Hereditary Cancers Solution to expand its current next-generation sequencing (NGS) offerings.
SOPHiA DDM for Hereditary Cancers Solution enables Krsnaa to provide high-quality NGS tests that help to evaluate for hereditary cancers. With SOPHiA GENETICS technology Krsnaa will advance its NGS offerings and help to democratize data-driven medicine.
“At SOPHiA GENETICS we pride ourselves on collaborating with cutting-edge laboratories and research institutions and working with them to bring data-driven medicine closer to all,” said Ken Freedman, Chief Revenue Officer, SOPHiA GENETICS. “Krsnaa is working to make precision medicine a reality for everyone in India and we are honoured to support their work by offering our Hereditary Cancer Solution to expand their NGS offerings.”
The use of next-generation sequencing (NGS) aids significantly in detecting biomarkers for hereditary cancers but also provides a vast and complex dataset for analysis. The SOPHiA DDM for Hereditary Cancers Solution uses artificial intelligence and machine learning with patented technologies to analyse raw NGS data, making it faster and easier for experts to analyse and interpret findings from NGS data with confidence.